Skip to main content

Imaging

Secukinumab Effective in Non-Radiographic Axial SpA

Aug 10, 2020

The PREVENT trial was a one year, phase III study that showed significant benefits when secukinumab (SEC) was given to patients with active non‐radiographic axial spondyloarthritis (nr‐axSpA) for 52 weeks.



To be enrolled patients had to have inflammatory low back pain and have either

Read Article
Correlation study of MRI and OA features finds meniscal extrusion, full thickness cartilage loss and osteophytes were associated with clinical knee pain.

Dr. John Cush RheumNow ( View Tweet)

Aug 10, 2020

Methotrexate Not Associated with Interstitial Lung Disease

Aug 05, 2020

A case-controlled study shows that methotrexate (MTX) use in rheumatoid arthritis (RA) is not associated with interstitial lung disease (ILD) according to a report in the European Respiratory Journal.



Researchers examined the associatioin by comparing 410 RA patients with

Read Article

IL-1 Blockade: A Treatment at Last for Osteoarthritis?

Aug 05, 2020

The interleukin (IL)-1β inhibitor canakinumab (Ilaris) showed promise for preventing the need for hip or knee replacement among patients with osteoarthritis in an exploratory analysis of data from a randomized clinical trial, investigators reported.

Among patients enrolled in CANTOS, the pooled

Read Article

Serial DEXA May Not Be Advisable

Jul 28, 2020

Does repeat bone mineral density (BMD) measurement predict subsequent fracture risk in postmenopausal women? A study published in JAMA suggests that a second BMD done 3 years after the initial DEXA did not further distinguish women who would be at a higher risk for a future hip fracture or

Read Article

RheumNow Podcast – COVID-19 Responds to Steroids (7.24.20)

Jul 24, 2020

Dr. Jack Cush reviews the News and Journal Reports from the past week on RheumNow.com.

Read Article
Single center retrospective Korean study of 1280 Ankylosing Spondylitis patients (595 exposed to TNFi) showed that TNFi was associated with significantly decreased Xray change rate (mSASSS) (β=−0.112, p=0.004). https://t.co/W4j0Ckt0R2

Dr. John Cush RheumNow ( View Tweet)

Jul 20, 2020

RheumNow Podcast – Lupus Mortality Declines, But… (6.26.20)

Jun 26, 2020

Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Read Article

Cosentyx FDA Approval for Non-Radiographic Axial Spondyloarthritis

Jun 18, 2020

Yesterday the FDA approved secukinumab (Cosentyx) for the treatment of patients with active non-radiographic axial spondyloarthritis (nr-axSpA). There are now three agents that are FDA approved for nr-axSpA: certolizumab, ixekizumab and now, secukinumab. 

Read Article

Day 4 - Top 3 from EULAR 2020

Jun 11, 2020

These were my top abstracts from Thursday, 4th of June at EULAR 2020:

Read Article
#EULAR2020 #op0079 ASAS-MRI group offers updated definition of the structural lesions in SI joints in AxSpA: -erosion in >=2 consecutive slices or in >=3 SIJ quadrants - fat lesions w/depth >1cm in >=1SIJ quadrant are high priority candidates @RheumNow
Olga Petryna DrPetryna ( View Tweet)
Jun 07, 2020
How often do you use MRI of peripheral joints for diagnosis or monitoring of PsA?

Olga Petryna DrPetryna ( View Tweet)

Jun 07, 2020
#EULAR2020 #op0182 delayed gadolinium-enhanced MRI study reveals proteoglycan loss in articulate cartilage in PsA associated w/severity of periarticular inflammation, synovitis &flexor tenosynovits but not bone erosion or prolypheration.
Olga Petryna DrPetryna ( View Tweet)
Jun 07, 2020
#eular2020 #op0314 5 y drug-free remission (5DFR) is rare in early AxSpA: 17%pts from DESIR cohort reach 5DFR. Shorter disease duration (<1.3y), lower BASDAI&ASAS-CRP & less peripheral involv more likely to achieve DFR. Imaging and biological data did not predict DFR @RheumNow

Olga Petryna DrPetryna ( View Tweet)

Jun 07, 2020
#EULAR2020 #op0327 AI stages knee OA radiograpgic chsnges ieth accuracy 91.8-99% in 95% of the cases. Would you prefer AI or human radiology readings for MSK imaging ? @RheumNow

Olga Petryna DrPetryna ( View Tweet)

Jun 07, 2020
Sustained clinical response shown over the 10 yrs of this German study in r-axSpA and nr-axSpA pts treated with ETN. No new safety signals.
Dr. Rachel Tate uptoTate ( View Tweet)
Jun 06, 2020
The Relative Diagnostic Utility of inflamm back pain criteria in inception cohort with PsO, Iritis, & Colitis Presenting With Undiagnosed Back Pain: All IBP criteria have poor diagnostic utility for dx of axSpA, esp in PsO Abs SAT0378 #EULAR2020 @RheumNow https:
Dr Philip Robinson philipcrobinson ( View Tweet)
Jun 05, 2020
Filgotinib was associated with significant reduction in SIJ erosion scores in axSpA: imaging data from the double-blind, randomized Tortuga trial #EULAR2020 @rheumnow THU0377 https://t.co/1b18Uyvo5j https://t.co/zBXCwGc0Q7
Dr Philip Robinson philipcrobinson ( View Tweet)
Jun 05, 2020
Replacing radiographic sacroiliitis with MRI structural damage doesn't change the classifciation of axSpA signifciantly @RheumNow #EULAR2020 Abstract SAT0384 https://t.co/MTTf4fHjYT
Dr Philip Robinson philipcrobinson ( View Tweet)
Jun 05, 2020
Preliminary definition of a +MRI for struc lesions in the SIJs in axSpA: Erosion in ≥2 consec slices or in ≥3 SIJ quad and fat lesion w depth >1cm in ≥1 SIJ quad are high priority for def an MRI struc lesion of axSpA.
Dr Philip Robinson philipcrobinson ( View Tweet)
Jun 05, 2020
Spanish COSPAR registry results reveal changes in axSpA pt gut microbiota which are associated with radiographic damage, disease activity, affectation of enthesis and axial mobility. #SAT0362 https://t.co/goo4Qkaqdb #EULAR2020 @RheumNow

Dr. Rachel Tate uptoTate ( View Tweet)

Jun 05, 2020
Another study shows that US guided SIJs in axSpA pts are safe and effective. Abstract #AB0642. #EULAR2020 @RheumNow https://t.co/KMPioCKr0n

Dr. Rachel Tate uptoTate ( View Tweet)

Jun 05, 2020

FDA Approves Taltz for Non-Radiographic Axial Spondyloarthritis

Jun 01, 2020

Today Eli Lilly announced that Taltz (ixekizumab) has received FDA approval for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA). Ixekizumab (an IL-17A inhibitor) would join certolizumab (TNF inhibitor) as the only 2 drugs approved by the FDA for nr-

Read Article

Systemic Sclerosis Future Therapies and Outcome Measures

May 19, 2020

Nagaraja, Khanna and colleagues have published an overview of current and future therapies in patients with systemic sclerosis (SSc) and have reviewed the potential outcome measures for this difficult autoimmune disorder. Notably there have been several novel agents studied in recent years,

Read Article

Cigarette Smoking and ANCA-Associated Vasculitis

May 05, 2020

JAMA Internal Medicine has reported that cigarette smoking associated with an increased odds of having antineutrophil cytoplasmic antibody–associated vasculitis (AAV) (especially MPO positive AAV) and is thereby a modifiable risk factor for AAV.

In a case-control study, 473 AAV

Read Article
×